Reversal of renal disease: is it enough to inhibit the action of angiotensin II? (Q36775273)

16 August 2017

1 reference

title

Reversal of renal disease: is it enough to inhibit the action of angiotensin II? (English)

1 reference

16 August 2017

1 reference

Dussaule JC

1

1 reference

PubMed ID

17396129

16 August 2017

Chatziantoniou C

series ordinal

2

1 reference

16 August 2017

30 March 2007

1 reference

Cell Death & Differentiation

16 August 2017

1 reference

16 August 2017

14

1 reference

16 August 2017

7

1 reference

16 August 2017

1343-1349

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cdd.4402143

16 August 2017

0 references

cites work

Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

Regression of renal vascular fibrosis by endothelin receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

Regulation of the mammalian cell cycle: a model of the G1-to-S transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

Activation of discoidin domain receptor 1 facilitates the maturation of human monocyte-derived dendritic cells through the TNF receptor associated factor 6/TGF-beta-activated protein kinase 1 binding protein 1 beta/p38 alpha mitogen-activated protei

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

Incidence and prevalence of ESRD. United States Renal Data System

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Epidermal growth factor receptor trans-activation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Renal and vascular hypertension-induced inflammation: role of angiotensin II.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Nitric oxide, oxidative stress, and progression of chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Vitamin E supplementation and cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Reversal of Glomerulosclerosis after High-Dose Enalapril Treatment in Subtotally Nephrectomized Rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Hepatocyte growth factor: new arsenal in the fights against renal fibrosis?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic inflammatory-induced mechanisms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

The discoidin domain receptor tyrosine kinases are activated by collagen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Interaction of discoidin domain receptor 1 isoform b (DDR1b) with collagen activates p38 mitogen-activated protein kinase and promotes differentiation of macrophages

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402143

7 January 2021

Identifiers

DOI

10.1038/SJ.CDD.4402143

1 reference

16 August 2017

1 reference

PubMed ID

17396129